August 10, 2020 -- Bristol Myers Squibb has paid $12 million to Dragonfly Therapeutics to license a fourth immunotherapy drug candidate from Dragonfly's TrinKet portfolio.
The deal will allow Dragonfly to further develop new natural killer cell-based treatment options for patients with cancer, autoimmune disease, and neurological conditions, it said. This is the fourth licensing agreement between the two firms since 2017.
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
